Journal of cardiovascular electrophysiology · 2025
Ivabradine Use in Premature Infants With Accelerated Idioventricular Rhythm.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ramdat Misier Nawin L, Doctor Pezad N, Tindel Kaitlin, de Groot Natasja M S, Ezekian Jordan E, Nguyen Hoang H
Аннотация
INTRODUCTION: Ivabradine has been recently introduced to treat focal atrial tachycardia and junctional ectopic tachycardia in children. Its use for treating ventricular tachyarrhythmias, specifically accelerated idioventricular rhythm (AIVR), remains limited.
METHODS AND RESULTS: We report two cases of premature infants with AIVR successfully treated with ivabradine as monotherapy after other antiarrhythmic agents had failed. The first infant had a structurally normal heart and the second infant a truncus arteriosus. In both patients, sinus rhythm was restored with ivabradine. Side effects only consisted of brief, hemodynamically insignificant episodes of bradycardia.
CONCLUSIONS: Ivabradine represents a promising antiarrhythmic agent for treating AIVR in preterm infants. Its ability to maintain hemodynamic stability in this age group makes ivabradine an attractive option for managing AIVR, especially in the postoperative setting. Further research is warranted to explore the safety, dosage, and mechanistic action of ivabradine for AIVR in the premature, neonatal infant patient population.
METHODS AND RESULTS: We report two cases of premature infants with AIVR successfully treated with ivabradine as monotherapy after other antiarrhythmic agents had failed. The first infant had a structurally normal heart and the second infant a truncus arteriosus. In both patients, sinus rhythm was restored with ivabradine. Side effects only consisted of brief, hemodynamically insignificant episodes of bradycardia.
CONCLUSIONS: Ivabradine represents a promising antiarrhythmic agent for treating AIVR in preterm infants. Its ability to maintain hemodynamic stability in this age group makes ivabradine an attractive option for managing AIVR, especially in the postoperative setting. Further research is warranted to explore the safety, dosage, and mechanistic action of ivabradine for AIVR in the premature, neonatal infant patient population.